Table 1.
Demographic and clinical characteristics of patients included into the ASV or control group
| ASV | Controls | |
|---|---|---|
| Number, n | 56 | 59 |
| Follow-up period (months) | 6.7 ± 3.2 | 6.2 ± 3.1 |
| Age (years) | 67.7 ± 9.5 | 62.5 ± 11.8 |
| Gender, males | 54 (96.4%) | 52 (88.1%)* |
| BMI (kg/m2) | 28.8 ± 4.8 | 27.3 ± 4.0 |
| Ischemic heart disease, n | 35 (62.5%) | 41 (60.5%) |
| Rhythm | ||
| Sinusrhythm, n | 35 (62.5%) | 35 (59.3%) |
| Atrial fibrillation, n | 10 (17.9%) | 12 (20.3%) |
| Pacemaker, n | 9 (16.1%) | 12 (20.3%) |
| Medication | ||
| ACE-inhibitors, ARB | 56 (100%) | 57 (96.6%) |
| β-Blocker | 54 (96.4%) | 56 (94.9%) |
| Diuretics | 45 (80.4%) | 54 (91.5%) |
| Aldosterone-RB | 32 (57.1%) | 41 (69.5%) |
| Digitalis | 20 (35.7%) | 23 (39.0%) |
ARB angiotensin receptor blocker, Aldosterone-RB aldosterone-receptor blocker
* p < 0.05, ASV versus control group